Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2551

Sigma-Aldrich

AZ32

≥98% (HPLC)

Synonym(s):

N-Methyl-4-(6-phenylimidazo[1,2-a]pyrazin-3-yl)benzamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H16N4O
CAS Number:
2288709-96-4
Molecular Weight:
328.37
MDL number:
MFCD31715431
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

[n]21c(ncc2c4ccc(cc4)C(=O)NC)C=NC(=C1)c3ccccc3

InChI

1S/C20H16N4O/c1-21-20(25)16-9-7-15(8-10-16)18-11-23-19-12-22-17(13-24(18)19)14-5-3-2-4-6-14/h2-13H,1H3,(H,21,25)

InChI key

LCRTUEXVVKVKBD-UHFFFAOYSA-N

Biochem/physiol Actions

AZ32 is an orally active, potent and selective ataxia telangiectasia mutated (ATM) kinase inhibitor (IC50 <6.2 nM; DNA-PK & PI3Ka IC50 =4.6 μM, hERG IC50 = 17.6 μM) with good aqueous solubility (24 μM) and blood-brain barrier (BBB) permeability in mice (free brain/plasma ratio = 0.26; 200 mg/kg p.o.). AZ32 exhibits radiosensitizing efficacy in human & murine glioma cultures by blocking radiation-induced DNA damage response (ATM pS1981 IC50 = 310 nM; 100% blockage of KAP1 pS824 & p53 pS15 at 300 nM; T98G cells). AZ32 (200 mg/kg/day p.o.) improves whole-head irradiation treatment survival rate among mice with brain GL261 tumors or NCI-H2228 NSCLC metastases in vivo.
Orally active, brain-penetrant, potent and selective ataxia telangiectasia mutated (ATM) kinase inhibitor with cancer radiosensitizing efficacy in vitro and in vivo.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000091212
0000091211
0000077972

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jeremy Karlin et al.
Molecular cancer therapeutics, 17(8), 1637-1647 (2018-05-18)
Inhibition of ataxia-telangiectasia mutated (ATM) during radiotherapy of glioblastoma multiforme (GBM) may improve tumor control by short-circuiting the response to radiation-induced DNA damage. A major impediment for clinical implementation is that current inhibitors have limited central nervous system (CNS) bioavailability;

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service